Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Nabs $74M in Private Stock Placement; Cash to Flesh Out Drug Pipeline

NEW YORK, Feb. 28 (GenomeWeb News) - Perlegen Sciences has closed $74 million in a private placement of its Series D Preferred Stock with new and existing investors, the company said today.


The company will use the equity financing "to continue in-licensing and developing a ... pipeline of late-stage drugs, exploiting Perlegen's ability to target the right drugs to the right patients," Robert Middlebrook, chief corporate development officer of Perlegen, said in a statement.


CSK Venture Capital led the financing, followed by new investors Brookside Capital, an affiliate of Bain Capital; Mizuho Securities; Glynn Capital Management; CapeSecurities; and "several other" USand European institutional investors.


Previous investors also participating in the financing included Affymetrix, Alex Zaffaroni, Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, and CMEA Ventures.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.